Keryx’s perifosine gets second orphan drug status
(AP) – 10 hours ago
NEW YORK — Keryx Biopharmaceuticals Inc. said Wednesday that its experimental cancer drug perifosine received orphan drug status as a treatment for neuroblastoma, a cancer that affects the nervous system and mostly strikes young children…
Perifosine also has orphan drug status as a colorectal cancer treatment, and the FDA has said it will conduct a faster-than-normal review of the drug in both colorectal cancer and multiple myeloma.
Read the entire release by going to: Associated Press story about Keryx Biopharmaceuticals’ perifosine
Promising! Feel good and keep smiling! Pat